GlassScriptPhysician profile
Kenneth J Howard
NPI 1447311238
$3,626.65
in general payments reported to CMS, 2019-2025
35 companies · $115 in 2025
The $115 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $744 · 2020: $322 · 2021: $173 · 2022: $1,002 · 2023: $1,067 · 2024: $204 · 2025: $115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,386.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,386.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $540.44 | 2021-2025 | |
| Novo Nordisk INC | $345.15 | 2019-2024 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $343.59 | 2019-2023 | Farxiga |
| Pfizer INC. | $313.02 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $249.07 | 2022-2023 | |
| Lilly USA, LLC | $218.02 | 2020-2023 | Jardiance, Trulicity, Mounjaro |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $162.96 | 2019-2020 | |
| Exact Sciences Corporation | $136.13 | 2023-2024 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $103.93 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $101.84 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $96.43 | 2021-2023 | Jynarque |
| Amgen INC. | $86.14 | 2019-2023 | Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $84.25 | 2019-2023 | |
| Glaxosmithkline, LLC. | $80.20 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $75.90 | 2019-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $65.68 | 2023 | Veozah |
| Merck Sharp & Dohme LLC | $63.54 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $61.99 | 2022-2023 | Gvoke Hypopen |
| Calliditas Therapeutics US INC. | $59.38 | 2023 | Tarpeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.52 | 2021-2023 | Jardiance |
| Alnylam Pharmaceuticals INC. | $49.39 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $40.74 | 2022 | |
| Boston Scientific Corporation | $38.92 | 2023 | |
| Abbott Laboratories | $33.06 | 2022-2024 | Freestyle Libre 3 |
| Dexcom, INC. | $31.01 | 2023 | Dexcom G6 Transmitter |
| Daiichi Sankyo INC. | $24.55 | 2023 | Injectafer |
| Inspire Medical Systems, INC. | $24.45 | 2024 | Inspire |
| Allergan, INC. | $24.01 | 2019 | |
| Dynavax Technologies Corporation | $21.81 | 2019 | |
| Biom'Up France Sas | $20.33 | 2020 | |
| Genzyme Corporation | $18.22 | 2022 | |
| Esperion Therapeutics, INC. | $15.93 | 2021 | |
| Sunovion Pharmaceuticals INC. | $15.24 | 2020 | |
| Melinta Therapeutics, LLC | $14.14 | 2019 | |
| Horizon Therapeutics Plc | $11.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Howard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.